Benzinga | Aug 4, 2021 08:03AM EDT

UroGen Pharma Q2 EPS $(1.17) Beats $(1.27) Estimate, Sales $13.00M Beat $10.21M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.27) by 7.87 percent. This is a 18.75 percent increase over losses of $(1.44) per share from the same period last year. The company reported quarterly sales of $13.00 million which beat the analyst consensus estimate of $10.21 million by 27.33 percent. This is a 3.39K percent increase over sales of $372.00 thousand the same period last year.